All In Biotech

NDA 022185 · Leo Pharma As

Taclonex

Betamethasone Dipropionate, Calcipotriene, Calcipotriene Hydrate · Topical

Last checked: Nov 20, 2026Latest source record: Jul 25, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

May 9, 2008

Approved uses

4

Original approval plus efficacy supplements

Registered trials

127

30 Phase 3, 11 recruiting

FAERS reports

1,723

791 serious, 37 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 30, 2017.

Taclonex ® Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 12 years and older. Taclonex Topical Suspension is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 12 years and older. ( 1 )

Mechanism: Taclonex Topical Suspension combines the pharmacological effects of calcipotriene hydrate as a synthetic vitamin D 3 analog and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in the treatment of plaque psoriasis of the scalp and body are unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • TACLONEX · BETAMETHASONE DIPROPIONATE 0.064%; CALCIPOTRIENE 0.005% · SUSPENSION, TOPICAL · Prescription · TE AB
  • TACLONEX · BETAMETHASONE DIPROPIONATE 0.064%; CALCIPOTRIENE HYDRATE 0.005% · SUSPENSION, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Betamethasone Dipropionate" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • psoriasis365
  • drug ineffective188
  • diarrhoea122
  • headache114
  • nausea114
  • pruritus100
  • arthralgia81
  • fatigue80
  • rash80
  • pain79
  • injection site pain60
  • erythema57

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20062
200712
200830
200929
201044
201162
2012123
2013114
201497
2015203
2016183
2017154
2018139
2019124
2020100
202158
202263
202390
202446
202536
202614

Recalls

1 FDA enforcement reports for this application.

  • Jan 16, 2017 · Class III · Terminated

    Labeling: Incorrect or missing package insert: the affected product was packaged with an out-of-date package insert (PI) dated February 2014.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Taclonex (Calcipotriene/Betamethasone)

2024 spending

$410K

Beneficiaries

81

202 claims

Per beneficiary

$5,057

$21.08 per unit

View as table
YearSpending
2020$2,216,475
2021$1,105,654
2022$651,830
2023$664,968
2024$409,582

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 226 on PubMed

Sponsor: Leo Pharma As

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.